SRX vs BTG, page-7

Tim Buckley, With Motley Fool & some posts on HC mentioning 57 price-earnings ratio for a growth stock, it's no wonder vol has crept in IMHO. If the idea of SIR-Spheres becoming a first-line treatment for liver cancer that patients receive at initial stages, makes investors nervous & anxious of a quick sell-off, rather than the opportunity for production and revenue certainty, then perhaps these investors need to find other stocks without as much as risk & without as much return. Some commentators want a lower price to take a "starting position", existing holders may not give them that chance with the Santa rally & January effect about to take hold. Currency helps, Tim, & low interest rates tend to support biopharma stocks, as K growth is needed rather than slow growth stocks (from corp finance research I have seen). Would not surprised to see SRX doing mid $30 unless clinical trials IMHO but DYOR. Why sell & miss out before the trials given company's history of results?